Navigation Links
Onyx Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/2/2011

and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: Nexavar being our only approved product; we may never receive marketing approval for carfilzomib or regorafenib; competition; failures or delays in our clinical trials or the regulatory process; dependence on our collaborative relationship with Bayer; if approved, we or Bayer, as the case may be, may be unsuccessful in launching, maintaining adequate supply of or obtaining reimbursement for carfilzomib or regorafenib; market acceptance and the rate of adoption of our products; pharmaceutical pricing and reimbursement pressures; serious adverse side effects, if they are associated with Nexavar, regorafenib or carfilzomib; government regulation; possible failure to realize the anticipated benefits of business acquisitions or strategic investments; protection of our intellectual property; the indebtedness incurred through the sale of our 4.0% convertible senior notes due 2016; and product liability risks. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission, as updated by Onyx's subsequent Quarterly Reports on Form 10-Q, under the heading "Risk Factors" for a more detailed description of these and other risks. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

(See attached tables)ONYX PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share amounts)(unaudited)Three Months EndedNine Months EndedSeptember 30, September 30, 2011201020112010Revenue: Revenue from collaboration agreement

$  75,041$63,696$ 
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
(Date:8/29/2014)... Aug. 29, 2014  United Therapeutics Corporation (NASDAQ: ... Court for the District of New Jersey ... company,s case against Sandoz, Inc. regarding United Therapeutics, Remodulin ... ruled that U.S. Patent No. 6,765,117 is both ... from marketing its generic product until the expiration of ...
(Date:8/29/2014)... -- ChemImage will present a workshop focused on hyperspectral ... Science Society,s 22 nd International Symposium on ... .  Forensic Scientists will be in attendance ... can bring to examination procedures. ... Development at ChemImage, will host a workshop during ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... , LARGO, Fla., Dec. 22 Unilens Vision Inc. ... that the shareholders of Unilens Vision Inc. voted overwhelmingly in ... at the extraordinary general meeting of its shareholders held yesterday. ... common shares (or 48.9%) were voted at the meeting with ...
... , HONG KONG, Dec. 22 /PRNewswire-Asia/ ... human health in a pioneering medical,field. On Dec. 20, 2009, ... Conference of Endoscopic Physicians. It,s been an honor,to have him ... benefiting human health. , "Endoscopic medicine ...
Cached Medicine Technology:Unilens Announces Extraordinary Meeting Results 2Olympic Winner Xiong Ni, Spokesperson for Endoscopic Medicine -- Chinese Minimally Invasive Advanced Technology Top in the World 2Olympic Winner Xiong Ni, Spokesperson for Endoscopic Medicine -- Chinese Minimally Invasive Advanced Technology Top in the World 3
(Date:8/30/2014)... (PRWEB) August 30, 2014 Ticket ... U.S. Open Tennis Championship tickets in NYC. ... promo/coupon code US-OPEN-2014 for all day session, evening session, ... group sales for this prestigious Grand Slam Tournament. , ... , 8/30/14 , US Open Tennis Championship: Men's/Women's 3rd ...
(Date:8/30/2014)... August 30, 2014 After offering ... country for the past several years, Dr. Roy ... Center have announced a scholarship program for veterans ... follows a meeting held this summer to discuss ... years, reporters have shed light on the large ...
(Date:8/30/2014)... TX (PRWEB) August 30, 2014 ... Disruptor Industry, 2009-2019 is a professional and in-depth ... industry. The report firstly reviews the basic information ... manufacturing technology. The report then explores global and ... product specification, capacity, Production value, and market share ...
(Date:8/30/2014)... 2014 Hundreds of Byetta lawsuits ( ... move forward in U.S. courts, Bernstein Liebhard LLP reports. ... July 31, 2014, Byetta and Bydureon (an extended-release version ... claims that allege the drugs caused pancreatitis, pancreatic cancer ... these claims are pending in a multidistrict litigation underway ...
(Date:8/30/2014)... Rapids, MI (PRWEB) August 30, 2014 ... residents, Forefront Dermatology is expanding with the addition of ... Dr. David Hammond who has provided leading-edge skin care ... with Forefront Dermatology. , “As a doctor, my ... they deserve. Through partnering with Forefront Dermatology, I’m better ...
Breaking Medicine News(10 mins):Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Expanding Care at the Forefront of Dermatology 2
... choice is influenced by physicians, preferences, research suggests ... kind of treatment received by a prostate cancer patient ... patient,s care, new research shows. , U.S. researchers analyzed ... and older who were diagnosed with prostate cancer between ...
... among normal-weight patients , TUESDAY, March 9 (HealthDay News) ... obese face tougher survival odds following treatment compared with ... finding builds on prior research that established that being ... the first place. , "Previous studies have shown that ...
... The ... health, fertility health, and women,s health. , ... Edmonton, Alberta (PRWEB) March 9, 2010 -- The Pregnancy Health ... gives Canadian women important and potentially life-changing information about pregnancy health, fertility health, and ...
... ... Nine innovative healthcare companies have been named Finalists and ... at the 12th Annual Innovations in HealthcareSM Awards Event, on April ... awards honor companies which have proven ways to lower the cost ...
... ... (APNY), a group of 18 established and highly regarded pediatrics practices in Queens, Nassau and ... of their care to extend to thousands more New York children than in the past. ... (Vocus) March 9, 2010 ...
... ... & Cold and Allergy Conference. It is a nasal-sinus irrigation system with a patented ... risk of sinus re-infection, growing concerns in the medical community. The device is also ... ...
Cached Medicine News:Health News:Doctor's Specialty Often Steers Prostate Cancer Care 2Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 2Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 3Health News:Obese Colon Cancer Survivors Face Poorer Prognosis 4Health News:Pregnancy Health Centre Launches Website to Help Women 2Health News:Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th 2Health News:Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th 3Health News:Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th 4Health News:Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th 5Health News:Long Island Pediatric Group Announces Policy Changes That Will Help More New Yorkers 2Health News:Long Island Pediatric Group Announces Policy Changes That Will Help More New Yorkers 3Health News:TechWorld Medicals NasalCare Nasal Cleanse Kit Named “Best New Product” at ECRM Cough & Cold and Allergy Conference 2Health News:TechWorld Medicals NasalCare Nasal Cleanse Kit Named “Best New Product” at ECRM Cough & Cold and Allergy Conference 3
Shielding's Fast Wrap Apron offers both comfort and ease of wearing. Adjustable back shoulder strap keeps apron snug. No ties or buckles....
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
Shielding's Economy Coat Apron offers the same features as our Standard Coat Apron with an open back allowing for freedom of movement, maximum flexibility and increased comfort....
Upper arm protection...
Medicine Products: